전체 8345
-
- Explorations of Inner Space: Human Microbial Communities in Health and Disease
-
- - Relman, David A.
National Institutes of Health (U.S.) (2010/11/18) - - Category : Wednesday Afternoon Lectures
- - Relman, David A.
- Complex microbial ecosystems occupy the cutaneous and mucosal surfaces of humans. Recent advances have highlighted both the tremendous diversity of these communities and their importance to host physiology, yet, we have only scratched the surface. Questions remain about the ecological processes that establish and maintain the human microbiota throughout life. Furthermore, basic features of the human microbial ecosystem remain poorly described, including variability in diversity, in space and time and between individuals. Assembly of the oral and the gut microbiota involve both stochastic historical events and contemporary environmental factors. We are exploring spatial patterning and the effects of perturbation on human microbial diversity. Approaches that combine ecological theory and statistics, sequence-based and other molecular assessments of community structure, and standardized clinical measurements may improve our understanding of health and disease within the communal human organism. By understanding the patterns of diversity associated with human health, we may be able to preserve and restore health more effectively. By recognizing the early signs of impending disturbance, we may be able to predict and avoid disease.
Dr. Relman currently serves as Chair of the Institute of Medicine？？？s Forum on Microbial Threats (U.S. National Academies of Science), as a member of the National Science Advisory Board for Biosecurity, and as a member of the Chemistry, Materials, Environmental and Life Sciences Directorate Review Committee (Chair, Biology Subcommittee) for Lawrence Livermore National Laboratory (DOE).
He has been a member of the Senior Advisory Group for Biodefense for the Office of the Secretary of Defense; Chair of the Board of Scientific Counselors of the National Institute of Dental and Craniofacial Research (NIH); and a member of the Board of Directors, Infectious Diseases Society of America (IDSA).
Dr. Relman co-chaired a three-year study at the National Academies of Sciences that produced a widely-cited report titled, ？？？Globalization, Biosecurity, and the Future of the Life Sciences？？？ (2006). He is a Fellow of the American Academy of Microbiology. Dr. Relman received the Squibb Award from the IDSA in 2001, and was the recipient of both the NIH Director？？？s Pioneer Award, and the Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation, in 2006.
The NIH Directors Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Explorations of Inner Space: Human Microbial Communities in Health and Disease
-
- John Doppman Memorial Lecture for Imaging Sciences - Oncologic Imaging: Endless Horizons
-
- - Hricak, Hedvig.
National Institutes of Health (U.S.) (2010/11/18) - - Category : Clinical Center Grand Rounds
- - Hricak, Hedvig.
- CC Grand Rounds
Hedvig Hricak, MD, PhD, Drhc
Chairman, Department of Radiology
Carroll and Milton Petrie Chair
Memorial Sloan-Kettering Cancer Center and
Professor of Radiology, Weill Medical College of Cornell University
For more information, visit
http://www.cc.nih.gov/about/news/grcurrent.html
John Doppman Memorial Lecture for Imaging Sciences - Oncologic Imaging: Endless Horizons
-
- Pediatric Drug & Medical Device Development: Setting Specifications & Defining Expectations
-
- - National Center for Research Resources (U.S.) (2010/11/18)
- - Category : Conferences
- Join your colleagues for a one-day conference focused on improving the pediatric drug and medical device development process in order to better meet the needs of pediatric populations. The purpose of this conference is to describe a set of specifications that a national child health clinical research infrastructure should address to effectively and efficiently develop drugs and medical devices for these pediatric populations. Through NCRR？？？s Clinical and Translational Science Award program, NCRR supports transformative research throughout the lifespan, and clinical research supporting child health has been an important part of this initiative from the start.
Leading experts and key stakeholders at the conference will discuss:
1. Collaboration opportunities with a national child health clinical research infrastructure;
2. Streamlining and improving the process from pediatric drug and device discovery to patient trial; and
3. Academic, industry, government and patient advocacy expectations.
For more information, including links to the full meeting agenda and an online registration form, visit the NCRR Web site at http://www.ncrr.nih.gov/news_&_events/upcoming_events/#ctsa-26.
Pediatric Drug & Medical Device Development: Setting Specifications & Defining Expectations
-
- Imaging Early Brain Development in Normal and High Risk Children
-
- - Gilmore, John H.
National Institute of Mental Health (U.S.). Office of the NIMH Deputy Director. (2010/11/18) - - Category : Special
- - Gilmore, John H.
- NIMH Deputy Director Candidate Lecture
Speaker: John H. Gilmore, M.D.
Thad and Alice Eure Distinguished Professor of Psychiatry and Vice Chair, Research and Scientific Affairs, Department of Psychiatry, University of North Carolina-Chapel Hill
Imaging Early Brain Development in Normal and High Risk Children
-
- NCI Board of Scientific Advisors - March 2009 (Day 1)
-
- - NCI Board of Scientific Advisors. Meeting 2009 : (2010/11/18)
- - Category : NCI Board of Scientific Advisors
Provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of the NCIs extramural research programs, and concept review of extramural program initiatives.
For more information, visit
http://deainfo.nci.nih.gov/advisory/bsa.htm
NCI Board of Scientific Advisors - March 2009 (Day 1)
-
- NCI Board of Scientific Advisors - March 2009 (Day 2)
-
- - NCI Board of Scientific Advisors. Meeting 2009 : (2010/11/18)
- - Category : NCI Board of Scientific Advisors
Provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of the NCIs extramural research programs, and concept review of extramural program initiatives.
For more information, visit
http://deainfo.nci.nih.gov/advisory/bsa.htm
NCI Board of Scientific Advisors - March 2009 (Day 2)
-
- Immune Memory for Abnormal Self and Immunosurveillance (NIH-Only)
-
- - Olivera J. Finn, Ph.D. (2010/11/18)
- - Category : NCI CCR Grand Rounds (NIH Only)
- Dr. Finn is Professor and Chair of the Department of Immunology, School of Medicine, University of Pittsburgh and the University of Pittsburgh Cancer Institute Immunology Program Leader. Dr. Finn received her PhD from Stanford University and has been working in the area of tumor immunology for over 20 years. Her laboratory was one of the first to study human T cell responses against tumors, and one of the first to identify a human tumor antigen, MUC1, capable of stimulating cytotoxic T cells. Her work led to the identification of a unique peptide epitope on that molecule culminating in
1993 in the approval of the synthetic version of this epitope as an investigational new drug by the FDA, which is now in Phase II clinical trials as a vaccine for pancreatic cancer, prostate cancer and colon cancer. Dr. Finn has recently undertaken a similar research strategy in lung cancer, and her laboratory has identified a cyclin B1 antigen in lung tumor cells. In addition to her interest in MUC1 and cyclin B1 as vaccine candidates and targets for immunotherapy, Dr. Finn is now directing her research towards the use of these and other molecules for early detection and prevention of cancer.
Dr. Finn has published over 160 papers and reviews and has served on editorial boards of many journals, including serving as Senior Editor for Cancer Research and Advisory Editor for the Journal of Experimental Medicine. She is a member of scientific advisory boards of several cancer centers and member of the NCI Board of Scientific Counselors. She is an active member of the American Association for Cancer Research where she serves on the Steering Committee of the Tumor Immunology Working Group. She is also active in the American Association of Immunologists where she served as President in 2007-2008. She is elected Counselor of the International Union of Immunology Societies.
Dr. Finn has trained 20 PhD and MD/PhD students and received the University of Pittsburgh Mentor of the Year Award. Her other honors include University of Pittsburgh Chancellor？？？s Distinguished Research Award and the University of Pittsburgh Cancer Institute Scientific Leadership Award. In 2009 she was named University of Pittsburgh Distinguished Professor. She holds Honorary Professorships at the University of Florence, Italy and the Fourth Military Medical University in Xhian, PRC and has been named Honorary Member of the Immunology Society of Serbia.
SELECTED REFERENCES:
1. Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, Finn OJ. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1125-31.
2. Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006; 66:6-9.
3. Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704-15.
NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. The lecture schedule is posted on various calendars of events, including at the following link:
http://www.bethesdatrials.cancer.gov/health-care-professionals/grand-rounds.aspx
Immune Memory for Abnormal Self and Immunosurveillance (NIH-Only)
-
- Immune Memory for Abnormal Self and Immunosurveillance (NIH-Only)
-
- - Finn, Olivera J.
National Cancer Institute (U.S.) (2010/11/18) - - Category : NCI CCR Grand Rounds (NIH Only)
- - Finn, Olivera J.
- Dr. Finn is Professor and Chair of the Department of Immunology, School of Medicine, University of Pittsburgh and the University of Pittsburgh Cancer Institute Immunology Program Leader. Dr. Finn received her PhD from Stanford University and has been working in the area of tumor immunology for over 20 years. Her laboratory was one of the first to study human T cell responses against tumors, and one of the first to identify a human tumor antigen, MUC1, capable of stimulating cytotoxic T cells. Her work led to the identification of a unique peptide epitope on that molecule culminating in
1993 in the approval of the synthetic version of this epitope as an investigational new drug by the FDA, which is now in Phase II clinical trials as a vaccine for pancreatic cancer, prostate cancer and colon cancer. Dr. Finn has recently undertaken a similar research strategy in lung cancer, and her laboratory has identified a cyclin B1 antigen in lung tumor cells. In addition to her interest in MUC1 and cyclin B1 as vaccine candidates and targets for immunotherapy, Dr. Finn is now directing her research towards the use of these and other molecules for early detection and prevention of cancer.
Dr. Finn has published over 160 papers and reviews and has served on editorial boards of many journals, including serving as Senior Editor for Cancer Research and Advisory Editor for the Journal of Experimental Medicine. She is a member of scientific advisory boards of several cancer centers and member of the NCI Board of Scientific Counselors. She is an active member of the American Association for Cancer Research where she serves on the Steering Committee of the Tumor Immunology Working Group. She is also active in the American Association of Immunologists where she served as President in 2007-2008. She is elected Counselor of the International Union of Immunology Societies.
Dr. Finn has trained 20 PhD and MD/PhD students and received the University of Pittsburgh Mentor of the Year Award. Her other honors include University of Pittsburgh Chancellor？？？s Distinguished Research Award and the University of Pittsburgh Cancer Institute Scientific Leadership Award. In 2009 she was named University of Pittsburgh Distinguished Professor. She holds Honorary Professorships at the University of Florence, Italy and the Fourth Military Medical University in Xhian, PRC and has been named Honorary Member of the Immunology Society of Serbia.
SELECTED REFERENCES:
1. Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, Finn OJ. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1125-31.
2. Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006; 66:6-9.
3. Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704-15.
NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. The lecture schedule is posted on various calendars of events, including at the following link:
http://www.bethesdatrials.cancer.gov/health-care-professionals/grand-rounds.aspx
Immune Memory for Abnormal Self and Immunosurveillance (NIH-Only)
-
- Demystifying Medicine - Arteriosclerotic cardiovascular disease: Number one killer and the Framingham experience
-
- - Daniel Levy, MD (NHLBI), Richard Cannon, MD (NHLBI), and Leslie Beisecker, PhD (NHGRI) (2010/11/18)
- - Category : Demystifying Medicine
- The course includes presentation of patients, pathology, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students, fellows, and staff, it is also of interest to medical students and clinicians. The course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components which are presented by NIH staff and outside invitees.
For more information, visit
http://www1.od.nih.gov/oir/DemystifyingMed
Demystifying Medicine - Arteriosclerotic cardiovascular disease: Number one killer and the Framingham experience
-
- Recombinant DNA Advisory Committee (RAC) March 2009 - Day 1
-
- - National Institutes of Health (U.S.). Recombinant DNA Advisory Committee. (2010/11/18)
- - Category : Recombinant DNA Advisory Committee
- The RAC is a technical committee whose goal is to consider the current state of knowledge and technology regarding recombinant DNA. This includes review of human gene transfer trials, and an assessment of the ability of DNA recombinants to survive in nature and the potential for transfer of genetic material to other organisms. It also considers hypothetical hazards and methods for monitoring and minimizing risks. Approximately one-third of the 15 members do not have scientific expertise but represent public interests and attitudes. This balance is intended to provide a forum for open public debate of social and scientific issues attendant to recombinant DNA research. The RAC has been overwhelmingly successful in achieving this goal.
For more information, visit the
Recombinant DNA Advisory Committee (RAC) Conference Web Site
Recombinant DNA Advisory Committee (RAC) March 2009 - Day 1
-
- Building Positive Relationships at Work
-
- - Jennifer Alfonso, MBA, MSW, LCSW-C (2010/11/18)
- - Category : Work/Life Center
- NIH Work Life Seminar
In todays economy, the work environment is increasingly stressful, as the demand to do more with less becomes a reality. The truth is that in order to be productive and less stressed, you need positive, supportive relationships at work. Interactions at work are numerous, complex and sometimes difficult, yet, having a strong support network can help you maximize your own success. It is important to develop cooperative interaction with colleagues and team members to enhance the quality of your work experience and find ways to boost productivity. This session will help you assess your interactions at work and provide tools to build the relationships you need to be productive and successful.
Creating a network of supportive people can be invaluable in the workplace by helping you problem solve or deal with unforeseen challenges. This seminar will outline the fundamentals in building positive working relationships, including the time it takes to nurture mutual respect, cooperation, and effective communications - the cornerstones of healthy professional relationships. The trainer will present ways to handle difficult interactions, increase your own receptivity to feedback, and other communication tips for improving your working relationships.
For more information, visit
http://wlc.od.nih.gov
Building Positive Relationships at Work
-
- Administrative Fellows Program Information Session
-
- - Melanie Keller, Executive Officer, Center for Scientific Research (2010/11/18)
- - Category : Special
- The NIH AFP Information Session will provide potential AFP applicants with a chance to learn more about the Program, meet with current professionals in the hiring career tracks, gain valuable information on applying for federal careers, and tour the beautiful NIH campus.
For more information, visit www.jobs.nih.gov/afp
Administrative Fellows Program Information Session
-
- Transforming Our Understanding and Treatment of Mental Illness
-
- - Sponsored by the Office of the NIMH Deputy Director (2010/11/18)
- - Category : Special
- NIMH Deputy Director Candidate Lecture
Speaker: Philip Sung-En Wang, M.D., Dr. P.H.
Director, Division of Services and Intervention Research,
National Institute of Mental Health
Transforming Our Understanding and Treatment of Mental Illness
-
- A Chemist (Re)discovers How The Immune System Kills TB
-
- - Dr. Barry Clifton (2010/11/18)
- - Category : Immunology
- Dr. Barry received his Ph.D. in organic and bioorganic chemistry in 1989 from Cornell University, studying the biosynthesis of complex natural products. Following postdoctoral research at Johns Hopkins University, Dr. Barry joined NIAIDs Rocky Mountain Laboratories. In 1998, he was tenured as chief of the Tuberculosis Research Section (TBRS). He is very involved in international activities to develop new chemotherapies for tuberculosis, serving as an advisor to the World Health Organization and the Global Alliance for TB Drug Development. Dr. Barry is a member of several editorial boards and has authored more than 60 research publications in tuberculosis since entering the field 10 years ago.
The TBRS is an integrated group of chemists, clinicians, and microbiologists dedicated to improving the chemotherapy of tuberculosis. Through a detailed understanding of Mycobacterium tuberculosis (Mtb)-the natural history of the disease, the advantages and shortcomings of current antibiotics, models for the evaluation of new antibiotics, and the underlying reasons for the development of drug resistance-section scientists work to identify new strategies to improve therapy. Translating these strategies into clinically useful drugs engages the chemistry portion of the group in areas such as chemical modification of promising new synthetic antitubercular compounds, identification and optimization of products derived from natural sources with antitubercular activity, and development of novel delivery methods and formulations.
Dont miss this talk!
http://www3.niaid.nih.gov/labs/aboutlabs/lcid/tuberculosisResearchSection/
For more information, visit
The Immunology Interest Group
A Chemist (Re)discovers How The Immune System Kills TB
-
- Making the Blastocyst: Linking cell Behaviour with Cell Fate
-
- - Rossant, Janet.
National Institutes of Health (U.S.) (2010/11/18) - - Category : Wednesday Afternoon Lectures
- - Rossant, Janet.
- Dr. Rossant has been recognized for her contributions to science with many awards, including the Killam Prize for Health Sciences, the March of Dimes Prize in Developmental Biology, the Conklin Medal from the Society for Developmental Biology, and the CIHR Michael Smith Prize in Health Research, Canada？？？s most prestigious health research award. She is a fellow of both the Royal Societies of London and Canada, and holds the Lombard Insurance chair in pediatric research at SickKids.
Dr. Rossant is a founding member and serves as Deputy Scientific Director of The Stem Cell Network. She also directs the Centre for Modelling Human Disease in Toronto, which is undertaking genome-wide mutagenesis in mice to develop new mouse models of human disease. She serves on the Governing Council of the Canadian Institutes of Health Research, and chaired the Institutes？？？ Working Group on stem cell research.
Dr. Rossant is a respected voice in the stem cell debate; she was involved with the National Academies of Science report on stem cell guidelines in the United States, and served on the International Society for Stem Cell Research (SSCR) task force charged with developing guidelines addressing the international diversity of cultural, political, legal and religious perspectives. Dr. Rossant has twice been named a Howard Hughes Medical Institute International Scholar.
From Dr. Rossant:
？？？The mouse blastocyst contains about 100 cells and only three distinct cell types. One cell type, the epiblast, gives rise to all cell types of the body and to pluripotent embryonic stem cells, while the other two cell types give rise to placental and other support cells and cell lines.
By studying both the embryo and its derived stem cells, we have been able to identify some of the key transcription factors specifying cell fate in both situations and used this information to derive new endoderm progenitor cell lines from human embryonic stem cells. But only by studying the embryo itself can we discover how cell behavior in the early developing embryo leads to restriction of cell fate by the blastocyst stage. I will describe our current model for blastocyst formation which implicates cell polarity, cell position and cell sorting in the final assembly of the organized blastocyst.？？？
The NIH Directors Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Making the Blastocyst: Linking cell Behaviour with Cell Fate
-
- Recombinant DNA Advisory Committee (RAC) March 2009 - Day 2
-
- - National Institutes of Health (U.S.). Recombinant DNA Advisory Committee. (2010/11/18)
- - Category : Recombinant DNA Advisory Committee
- The RAC is a technical committee whose goal is to consider the current state of knowledge and technology regarding recombinant DNA. This includes review of human gene transfer trials, and an assessment of the ability of DNA recombinants to survive in nature and the potential for transfer of genetic material to other organisms. It also considers hypothetical hazards and methods for monitoring and minimizing risks. Approximately one-third of the 15 members do not have scientific expertise but represent public interests and attitudes. This balance is intended to provide a forum for open public debate of social and scientific issues attendant to recombinant DNA research. The RAC has been overwhelmingly successful in achieving this goal.
For more information, visit the
Recombinant DNA Advisory Committee (RAC) Conference Web Site
Recombinant DNA Advisory Committee (RAC) March 2009 - Day 2
-
- Computer-based Decision Support in the Emergency Department
-
- - Dominik Aronsky, M.D., Ph.D., Assistant Professor of Biomedical Informatics and Emergency Medicine, Vanderbilt University (2010/11/18)
- - Category : Special
- NLM Informatics Lecture Series
The Emergency Department is a fast-paced, information intensive environment that can benefit from improved information management. The presentation will discuss how an integrated information system infrastructure can support providers to deliver high-quality patient care, optimize operational activities, and facilitate clinical and informatics research studies in the Emergency Department. Illustrative examples will include improvement of pneumonia-care processes, implementation of asthma guidelines, and forecasting Emergency Department overcrowding.
Dr. Dominik Aronsky is an Assistant Professor of Biomedical Informatics and Emergency Medicine at Vanderbilt University. He completed his MD degree at the University of Berne (Switzerland) and earned a PhD in Medical Informatics from the University of Utah in 2000. Dr. Aronsky is interested in interdisciplinary research with a focus on developing, implementing, integrating, and evaluating computerized decision support systems for real time, clinical applications. He is interested in collaborating closely with clinicians and other researchers to develop and evaluate integrated systems that include machine learning methods in support of patient care. He is also interested in the study design and the clinical evaluation of medical informatics systems.
Computer-based Decision Support in the Emergency Department
-
- CC Grand Rounds: (1) Understanding and Ensuring the Quality of Cellular and Gene Therapies Through Science and Regulation (2) The Use of Molecular Assays to Assess the Potency of Cellular Therapies
-
- - Wonnacott, Keith.
National Institutes of Health (U.S.) (2010/11/18) - - Category : Clinical Center Grand Rounds
- - Wonnacott, Keith.
- CC Grand Rounds
Keith Wonnacott, PhD
Chief, Cellular Therapies Branch
Center for Biologics Evaluation and Research, FDA
David Stroncek, MD
Chief, Cell Processing Section
Department of Transfusion Medicine, CC
For more information, visit
http://www.cc.nih.gov/about/news/grcurrent.html
CC Grand Rounds: (1) Understanding and Ensuring the Quality of Cellular and Gene Therapies Through Science and Regulation (2) The Use of Molecular Assays to Assess the Potency of Cellular Therapies
-
- Science in the Public Health - Ive Got Rhythm, Circadian Rhythm! (HHS Only)
-
- - Dorothy Duke and Bill Elwood (2010/11/18)
- - Category : STEP (HHS Only)
- Science in the Public Health
Circadian (about a day) rhythms affect your behavior and nearly every physiological process. Variations of circadian rhythms are associated with heart disease, obesity, depression, and the efficacy of chemotherapy. They also affect our ability to adjust to night shift work and daylight savings time! Come to this STEP forum to learn more about circadian rhythms？？？what they are, what aspects of human health and disease they control, and what animal and human studies have taught us. You？？？ll learn how we synchronize our rhythms to the day-and-night cycles in our environment, the differences and similarities among larks and night owls, how circadian rhythms affect bodily functions, and how we might rely on circadian rhythms for future research in prevention and treatment. This training is recommended for ESA Credit.
For more information, visit
I？？？ve Got Rhythm, Circadian Rhythm!
Science in the Public Health - Ive Got Rhythm, Circadian Rhythm! (HHS Only)
-
- CTSA Pre-Submission Meeting March 2009
-
- - NCRR (2010/11/18)
- - Category : Special
- A pre-submission video cast will be conducted on 3/05/2009, between 2:00 and 4:00 pm at which NCRR and other NIH staff will explain the goals and objectives of the CTSA program. The current CTSA RFA has several changes compared with the previous RFA, RFA-RM-08-002, which was released December 27, 2007. All prospective applicants are invited to submit questions in advance, and to view the meeting through video cast (web cast). Questions may be submitted in advance though a live event feedback form.
CTSA Pre-Submission Meeting March 2009